Skip to main content
S&P 5007,591.69+0.94%DOW52,326.41+0.18%NASDAQ25,452.79+1.54%BTC$73,535.00-0.21%ETH$2,047.56-0.73%GOLD$4,036.60+0.16%OIL$87.14+1.28%
Smart Investors Daily
SID Premium
HA

NYSE · HAE

Haemonetics Corporation

Healthcare · Medical - Instruments & Supplies

$122.36

Up+$4.15 (+3.51%)

Updated Nov 11, 2026, 12:37 PM

SID Score

6.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.12B
P/E ratio
23.87
Dividend yield
0.00%
52-week range
$51.00 – $132.00
Volume
797.95K
Avg. volume
976.76K

Price performance · HAE

HAE price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 10, 2026

HAE closed at $122.36 after 21 trading sessions, up 0.53% for the selected period.

Last close
$122.36
Period change
+0.53%
Period low
$116.16
Period high
$127.42
Daily close
View OHLC price history
HAE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 10, 2026$117.90$123.08$116.68$122.36797.95K
Nov 9, 2026$121.16$122.97$117.4801$118.21999.32K
Nov 6, 2026$121.16$123.75$116.79$119.93834.68K
Nov 5, 2026$126.06$132.00$121.22$124.111.3M
Nov 4, 2026$122.16$128.825$121.26$127.42982.03K
Nov 3, 2026$119.07$121.44$119.00$120.28834.6K
Nov 2, 2026$120.36$121.485$119.075$120.14678.59K
Oct 30, 2026$120.50$120.50$118.395$119.65453.35K
Oct 29, 2026$118.85$120.54$117.97$119.79558.54K
Oct 28, 2026$119.40$120.79$117.71$118.32501.82K
Oct 27, 2026$118.69$121.9099$117.70$119.97900.89K
Oct 26, 2026$118.62$119.43$117.49$119.19469.74K
Oct 23, 2026$115.50$119.20$115.4924$118.51777.38K
Oct 22, 2026$117.70$118.68$116.07$116.16365.13K
Oct 21, 2026$117.49$119.14$116.65$117.11843.47K
Oct 20, 2026$119.50$120.50$117.205$118.21585K
Oct 19, 2026$118.07$119.8199$117.00$118.73392.22K
Oct 16, 2026$121.83$121.84$118.1914$118.28471.52K
Oct 15, 2026$122.20$122.46$118.65$121.29747.65K
Oct 14, 2026$121.81$122.53$119.55$121.11592.14K
Oct 13, 2026$122.80$123.77$121.045$121.72829.19K

Latest HAE news

The latest Smart Investors Daily articles mentioning HAE.

Stock researchCompany · Overview

HAE research

Overview

Company profile and research snapshot.

Company profile

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$82.00
Implied upside
—
Analysts
—
HAE recent ratings
DateFirmRatingTarget
Nov 6, 2026CitigroupBuy—
Nov 6, 2026Barrington ResearchOutperform—
Nov 5, 2026BTIGBuy—
Oct 9, 2026MizuhoOutperform—
Oct 9, 2026Barrington ResearchOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 8, 2026

Should Raised Revenue Outlook Require Action From Haemonetics Stock Investors?

Haemonetics reported second quarter fiscal 2027 sales of US$357.76 million and net income of US$46.31 million, alongside higher earnings per share than a year earlier, and raised its full-year reported revenue growth outlook to a range of 8% to 11%. The extended CSL partnership, which is tied to recurring disposable revenue, provides additional clarity for Haemonetics’ plasma collection franchise and its broader earnings profile. Investors will now be evaluating how Haemonetics’ raised...

Yahoo · Nov 7, 2026

Haemonetics (HAE) Stock May Be 34% Undervalued On Cash Flow

Haemonetics has delivered a strong run in recent years, so the obvious question for anyone looking at the stock today is whether the current share price still lines up with the cash the business is expected to generate. With the market now pricing Haemonetics at recent levels around US$119.93, the focus naturally shifts to what its cash flows can support over time. Over the past 5 years the stock has returned 100.0%, which puts real weight on whether that share price performance is backed by...

Yahoo · Nov 7, 2026

Haemonetics Q2 Earnings Call Highlights

Haemonetics (NYSE:HAE) raised its fiscal 2027 revenue growth outlook after reporting double-digit organic growth in its second quarter, but lowered its operating margin expansion forecast as it invests to support an expanded relationship with plasma collector CSL. The company reported 10% organic r

Yahoo · Nov 7, 2026

Haemonetics (HAE) Beats Q2 Expectations, Is The Stock Still Cheap?

Haemonetics (HAE) just posted second quarter results that topped expectations, raised its full year revenue growth outlook, and pointed to a deeper CSL partnership that could support recurring plasma related sales. Haemonetics has ridden a clear upswing, with the share price logging a 36.5% return over 90 days and 49.9% year to date. The 75.4% total shareholder return over the past 12 months points to momentum building as investors reassess both growth prospects and risk. Scan for other...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By